Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.765 USD | +2.02% | -1.81% | -87.99% |
Chart calendar Amylyx Pharmaceuticals, Inc.
Upcoming events on Amylyx Pharmaceuticals, Inc.
Past events on Amylyx Pharmaceuticals, Inc.
2024-05-15 11:40 am | BofA Securities Health Care Conference |
2024-05-09 08:00 am | Q1 2024 Earnings Call |
2024-05-09 07:00 am | Q1 2024 Earnings Release |
2024-04-16 11:15 am | American Academy of Neurology Meeting |
2024-04-10 01:30 pm | HELIOS Phase 2 Clinical Trial Results Call |
2024-03-08 08:00 am | AMX0035 Phase III Clinical Trial Results Call |
2024-03-04 06:00 pm | Muscular Dystrophy Association Clinical & Scientific Conference |
2024-02-22 08:00 am | Q4 2023 Earnings Call |
2024-02-22 07:00 am | Q4 2023 Earnings Release |
2023-12-07 12:45 pm | Motor Neurone Disease Association International Symposium - Poster No: TST-12 |
2023-12-07 11:45 am | Motor Neurone Disease Association International Symposium - Poster No: CLT-11 |
2023-12-07 11:45 am | Motor Neurone Disease Association International Symposium - Poster No: CW-06 |
2023-12-06 11:45 am | Motor Neurone Disease Association International Symposium - Poster No: BIO-14 |
2023-12-06 11:45 am | Motor Neurone Disease Association International Symposium - Poster No: CLT-10 |
2023-12-06 11:45 am | Motor Neurone Disease Association International Symposium - Poster No: CLT-30 |
2023-11-28 02:10 pm | Evercore ISI HealthCONx Conference |
2023-11-09 08:00 am | Q3 2023 Earnings Call |
2023-11-09 07:00 am | Q3 2023 Earnings Release |
2023-10-19 12:00 pm | Neuro PSP and CBD International Research Symposium |
2023-10-05 04:30 pm | Northeast ALS Consortium Meeting - Poster Number: 125 |
Annual results
Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,29 0,40 -28.08% | 22,2 4,41 403.57% | 381 380 0.27% | 94,3 |
EBITDA Million USD | Released Forecast Spread | 0,00 | 0,00 -86,7 - | -201 -212 5.05% | 39,9 53,1 -24.81% | -193 |
EBIT Million USD | Released Forecast Spread | 0,00 | -82,7 -97,2 14.95% | -201 -212 4.84% | 38,8 52,9 -26.65% | -226 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -87,9 -92,0 4.42% | 0,00 0,00 - | 54,3 69,4 -21.78% | -289 |
Net income Million USD | Released Forecast Spread | -42,3 | -87,9 -97,2 9.5% | -198 -207 4.16% | 49,3 63,0 -21.78% | -183 |
EPS USD | Released Forecast Spread | -6,96 | -13,4 -15,4 13.03% | -3,39 -3,54 4.15% | 0,70 0,90 -22.38% | -2,67 |
Announcement Date | 26/04/21 | 30/03/22 | 13/03/23 | 22/02/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 0,06 - | 0,00 0,08 - | 0,35 0,08 314.02% | 21,9 4,72 363.26% | 71,4 59,7 19.75% | 98,2 92,1 6.6% | 103 114 -9.65% | 108 107 1.31% | 88,6 98,3 -9.87% | 8,53 | 0,00 | 0,00 | 0,00 |
EBIT Million USD | Released Forecast Spread | -47,8 -33,0 -44.72% | -54,3 -48,5 -11.89% | -54,7 -56,9 3.88% | -44,6 -53,4 16.47% | -2,05 -19,7 89.57% | 20,2 3,45 486.33% | 18,7 29,0 -35.46% | 1,93 14,6 -86.79% | -11,7 -9,05 -28.88% | -67,0 | -53,7 | -44,0 | -35,3 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -47,7 -50,0 4.6% | 1,40 -9,80 114.32% | 24,0 6,90 247.93% | 22,4 30,6 -26.76% | 6,48 21,6 -70.01% | -119 -15,5 -664.77% | -74,4 | -55,1 | -41,3 | ||||
Net income Million USD | Released Forecast Spread | -47,8 -39,5 -21.03% | -54,1 -50,2 -7.78% | -53,8 -56,3 4.46% | -42,7 -51,3 16.78% | 1,57 -15,1 110.43% | 22,1 2,80 687.42% | 20,9 30,0 -30.33% | 4,73 16,5 -71.3% | -119 0,60 -20065.21% | -47,5 | -37,6 | -29,6 | |
EPS USD | Released Forecast Spread | -0,93 -0,75 -24.83% | -0,93 -0,92 -1.64% | -0,92 -0,97 4.66% | -0,65 -0,81 19.75% | 0,02 -0,22 109.09% | 0,31 -0,04 985.71% | 0,30 0,42 -29.13% | 0,07 0,23 -69.75% | -1,75 0,01 -23433.33% | -0,70 | -0,55 | -0,44 | |
Announcement Date | 12/05/22 | 11/08/22 | 10/11/22 | 13/03/23 | 11/05/23 | 10/08/23 | 09/11/23 | 22/02/24 | 09/05/24 | - | - | - | - |
2024-07-11 02:00 am | BONESUPPORT HOLDING AB: Q2 2024 Earnings Release |
2024-07-15 | SWEDISH ORPHAN BIOVITRUM AB: Q2 2024 Earnings Release |
2024-07-22 | BIOGEN INC.: Q2 2024 Earnings Release (Projected) |
2024-07-23 02:00 am | BIOGAIA AB: Q2 2024 Earnings Release |
2024-07-23 | SAMSUNG BIOLOGICS CO.,LTD.: Q2 2024 Earnings Release (Projected) |
2024-07-24 | PHARMA MAR, S.A.: Q2 2024 Earnings Release (Projected) |
2024-07-24 | GRIFOLS, S.A.: Q2 2024 Earnings Release (Projected) |
2024-07-25 01:00 am | UCB: Q2 2024 Earnings Release |
2024-07-25 | SK BIOSCIENCE CO.,LTD.: Q2 2024 Earnings Release (Projected) |
2024-07-29 | BIOMARIN PHARMACEUTICAL INC.: Q2 2024 Earnings Release (Projected) |
Past sector events for Amylyx Pharmaceuticals, Inc.
2024-05-23 05:43 am | CONCORD BIOTECH LIMITED: Q4 2024 Earnings Release |
2024-05-14 11:35 am | GRIFOLS, S.A.: Q1 2024 Earnings Release |
2024-05-12 | ALTEOGEN INC.: Q1 2024 Earnings Release (Projected) |
2024-05-09 | PHARMARESEARCH CO., LTD.: Q1 2024 Earnings Release |
2024-05-09 | MEDY-TOX INC.: Q1 2024 Earnings Release |
2024-05-09 04:05 pm | AVIDITY BIOSCIENCES, INC.: Q1 2024 Earnings Release |
2024-05-09 04:05 pm | ADMA BIOLOGICS, INC.: Q1 2024 Earnings Release |
2024-05-09 02:30 am | NXERA PHARMA CO., LTD.: Q1 2024 Earnings Release |
2024-05-08 | HUGEL, INC.: Q1 2024 Earnings Release |
2024-05-08 04:16 pm | CATALYST PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- AMLX Stock
- Calendar Amylyx Pharmaceuticals, Inc.